Find an expert

Dr Nicole Warrington is a NHMRC Emerging Leadership Fellow at the University of Queensland Institute for Molecular Bioscience. She has a strong background in statistical genetics and has been actively working towards understanding the genetic determinants of early life growth. Dr Warrington studied a Bachelor of Science at Victoria University in Wellington, New Zealand, majoring in Mathematical Statistics and Psychology. She then completed an honours degree at The University of Western Australia, where she developed a keen interest for genetics, and was subsequently awarded an Australian Postgraduate Award to complete her PhD in statistical genetics and life-course epidemiology. During her PhD she spent time at the University of Toronto to gain experience in statistical modelling methods for longitudinal growth trajectories and conducted the first genome-wide association study of longitudinal growth trajectories over childhood. After completing her PhD, Dr Warrington started at the University of Queensland and focused on using genetics to inform about the relationship between birth weight and cardio-metabolic diseases in later life. She pioneered a new statistical method to partition genetic effects on birth weight into maternal and fetal components, and combined this method with a causal modelling approach, Mendelian randomization. This method was instrumental in demonstrating the relationship between birth weight and adult hypertension is driven by genetic effects, over-turning 30 years of research into the effects of intrauterine programming. More recently, her research focus has broadened to determine whether rapid weight growth across early life, including fetal development, childhood and adolescence, causally increases risk of cardio-metabolic disease and in doing so, hopes to identify optimal times across the life-course where interventions could reduce the incidence of cardio-metabolic diseases.

Maiden name: Ellen Maree Leslie

Dr Ellen Wessel is a Research Fellow in the School of Public Health, with backgrounds in both public health and criminology. Her research interests include women's health, alcohol and other drug use, and policing.

Associate Professor West is a molecular microbiologist, expert in bacterial pathogenesis. He is Head of “Tuberculosis Research” in the School of Chemistry and Molecular Biosciences, University of Queensland. Nick has a particular interest in drug development for TB. His research utilises modern molecular technologies to identify the genetic requirements for Mycobacterium tuberculosis to cause Tuberculosis (TB) with these genetic discoveries translated into novel antibiotic therapies. Research within his group falls largely into one of the following four themes: Essential Gene Identification in M. tuberculosis, Understanding TB Latency, Targeted TB Drug Development and Improving TB Vaccination.

Nick conducted postdoctoral research at the University of Oxford and Imperial College London. Returning to Australia in 2004, he spent several years at Sydney’s Centenary Institute as an Associate Faculty member before relocating to University of Queensland in 2012. In addition to drug development, Nick’s research portfolio includes programmes of vaccine and diagnostic development and testing.

Dr Wheeler is a proud Ngarabal person and Accredited Exercise Scientist (ESSA). Dr Wheeler specilises in implementation science in partnership with Aboriginal and Torres Strait Islander peoples and communities.

Dr Wheeler was the first Aboriginal person to graduate with a PhD from the University of the Sunshine Coast.

Dr Wheeler’s research examines how Aboriginal and Torres Strait Islander communities can co-design programs that build community capacity and engage children and young peoples in a broad range of development areas. Dr Wheeler’s research strengths consist co-designing physical movement-based programs, ensuring a trauma informed and culturally-responsive approach towards community engagement and empowerment.

Dr Wheeler has led high performing teams working on education programs that support Aboriginal and Torres Strait Islander families through a strength-based and holistic framework. Extending this work, Dr Wheeler's research focuses on developing the Aboriginal and Torres Strait Islander workforce to better address the complex health needs of community. Dr Wheeler has provided FIrst Nations leadership to a range of projects that have catered for the diversity of Aboriginal and Torres Strait Islander communities, and through this experience has partnered to deliver diverse governance solutions and educational engagement frameworks.

Dr Wheeler also specialises in biomechanics, sport analytics and performance analysis as well as strength and conditioning research. Dr Wheeler works currently with a range of sporting organisations to implement best-practice sport servicing, testing and athlete management to achieve excellence. Dr Wheeler is the lead researcher in partnership with Indigenous Basketball Australia. Dr Wheeler has worked with a variety of professional sporting organisations and teams such as the Wallabies, Brumbies Rugby and World Rugby as well as the Australian Institute of Sport, Canberra Raiders, Canberra Comets, Canberra Meteors and GWS Giants. Dr Wheeler co-design training programs to promote optimal performance in a range of sports. Dr Wheeler is a passionate about how sport and exercise can be used to enrich community as well as health and wellbeing for Aboriginal and Torres Strait Islander peoples.

Dr Wheeler is the Chair of the ESSA Aboriginal and Torres Strait Islander Strategy Working Group for Exercise and Sport Science Australia.

Dr Wheeler is the Director of Aboriginal and Torres Strait Islander Strategy for the School of Human Movement and Nutrition Sciences.

Dr Wheeler is the Program Convenor for Bachelor of Exercise and Sport Sciences, the University of Queensland.

Dr Wheeler was named in the top 52 Aboriginal and Torres Strait Islander people changing the world from COSMOS.

Awards

2022 Aboriginal and Torres Strait Islander Scientist Award from the Australian Academy of Science

2022 LSQ Merck Life Science Rural and Regional Service Award from Life Sciences Queensland

2020 Accredited Exercise Scientist of the Year Award from Exercise and Sport Science Australia

2021 Science Peoples Choice Award from National Science Week

2021 Outreach Award from National Science Week

2020 Science Leadership Excellence Award from National Science Week

2017 NAIDOC Award from Fraser Coast NAIDOC Committee

Brooke-Mai is a Lecturer in Speech Pathology and a Certified Practicing Speech Pathologist. Her research interests include the rehabilitation of motor speech disorders, brain mechanisms underpinning speech recovery, and the application of telerehabilitation to improve access to speech pathology services.

Dr Melanie White heads the Dynamics of Morphogenesis Lab at the Institute for Molecular Bioscience (IMB), University of Queensland and is an ARC Future Fellow. She completed a PhD in Neuroscience at University College London followed by postdoctoral research at The University of Edinburgh. During this time Mel engineered viruses to modulate gene expression in the brain to investigate neuronal function and as a therapeutic approach for neurodegenerative disease. Her work was published in Neuron and PNAS, featured in Nature Reviews Neuroscience and received extensive international media coverage (including the BBC and The Guardian).

In 2012 Mel switched fields to apply quantitative imaging in developmental biology. Her work revealed key mechanisms driving the earliest morphogenetic events in mammalian embryogenesis and was published in Cell, Science, Nature Cell Biology, Developmental Cell and Nature Protocols. Her research was featured on the cover of multiple journals including Cell and she was awarded the inaugural American Society for Cell Biology Porter Prize for Research Excellence (2018).

In 2020, Mel joined the IMB where she will combine her passion for neuroscience and developmental biology to investigate the dynamics of neural tube morphogenesis.

Research overview

The brain and the spinal cord control most of the functions of the body and the mind, yet the dynamics of how they first form is poorly understood. Both structures arise from a common precursor, the neural tube, which forms very early in embryonic development. To generate the forces that sculpt and shape the neural tube, changes in cellular architecture must be tightly coordinated in space and time. These morphological rearrangements occur concurrently with biochemical signalling pathways that specify early neural cell fates.

Our research aims to understand how cellular properties and transcriptional regulators interact with mechanical forces in real time to direct vertebrate neural tube formation and neural cell fate specification. We study the dynamics of neural tube formation by applying advanced imaging technologies in transgenic avian models and human stem cell models.

Professor Whiteford is Director of the Queensland Centre for Mental Health Research. His research interests are in psychiatric epidemiology and burden of disease measurement, mental health policy and service reform.

Professor Whiteford trained in medicine, psychiatry and health policy at the University of Queensland, Stanford University and the Australian National University. He has held senior clinical and administrative positions, including those of Director of Mental Health in the Queensland and Federal governments in Australia. He worked for ten years on the design and implementation of Australia’s Mental Health Strategy and was Chairman of the Working Group which oversaw this initiative. He was appointed to the first mental health position in the World Bank in Washington DC with the task of developing the Bank’s capacity to respond to the rising global burden of mental, neurological, and substance use disorders. He has worked as a consultant to national governments, the Commonwealth and State governments in Australia, the World Bank, and the World Health Organisation.

Associate Professor

Pharmacy Australia Centre of Excellence Email: karen.whitfield@uq.edu.au

Dr Karen Whitfield is an Associate Professor within the School of Pharmacy and is the Program Lead for the Master of Clinical Pharmacy.https://future-students.uq.edu.au/study/programs/master-clinical-pharmacy-5718

Karen was awarded the Research Excellence Award for Research Support - Metro North Health Service in 2020 and the Australian Clinical Pharmacist awarded by the Society of Hospital Pharmacists of Australia in 2017

Karen has worked at a number of different hospital including Royal Brisbane and Women's Hospital, Leicester Royal Infirmary, Leicester General Infirmary, North Staffordshire Hospital Trust (Surgical and Paediatric Directorate Pharmacist), The Townsville Hospital. Most recently she has worked at the Royal Brisbane and Women’s Hospital (from 2015-2021) holding several positions including, Team Leader Women's and Newborns and Assistant Director Cancer Care Services. She has also held a number of teaching positions including, Sr Lecturer James Cooke University, Teacher Practitioner with Medicines Services Queensland and lecturer with the University of Queensland.

Her specialist interests include Women's Health and Neonatology

She completed a Diploma in Hospital Pharmacy (1991), Masters in Clinical Pharmacy (1996) and completed her PhD at Aston University in 2002 under the supervision of Dr John Marriott and Dr Keith Wilson at the Birmingham Children’s Hospital UK, investigating sedatives in the Paediatric Intensive Care Unit.

Karen has presented work Nationally and Internationally at several Seminars and Conferences including, Life Long Learning for Pharmacists Conference (Dublin 2020, Croatia 2016), FIP webinar series ‘Hearing from our Hero’s’ (2020), Monash Pharmacy Education Symposium (2019), MM2018 SHPA Conference Brisbane (2018), Neonatal and Paediatric Pharmacists Conference UK (2015), Society of Obstetric Medicine Australia and New Zealand (Melbourne 2015).

Jocelyn Widagdo received her PhD in 2011 from the University of New South Wales. After a short period of postdoctoral training at the Johns Hopkins University in Baltimore, USA, Dr Widagdo returned to Australia in 2012 and joined the Queensland Brain Institute, the University of Queensland, where she is currently a Research Fellow at the Clem Jones Centre for Ageing Dementia Research. Her research aims to understand how the process of synaptic plasticity, learning and memory are underpinned by dynamic regulation of DNA, RNA and proteins, and consequently, how they contribute towards the pathophysiology of neurodegenerative diseases and neuropsychiatric disorders. Her works were published in journals such as The Proceedings of the National Academy of Sciences USA, Journal of Neuroscience, and Cell Reports, and have attracted more than 2000 citations. Dr Widagdo's research has been supported by the Australian Research Council (Discovery Early Career Researcher Fellowship, 2017; Discovery Project grant, 2023).

Dr Lahann Wijenayake is the Head of Orthopaedic Surgery at The University of Queensland. He is a Brisbane based orthopaedic surgeon having obtained his FRACS and FAorthA through the Royal Australasian College of Surgeons. He is also an Associate Fellow of the Royal Australian College of Medical Administrators. Dr Wijenayake is a surgeon at the Queensland Children's Hospital. He has a keen interest in medical student teaching as well as research in the field of paediatric orthopaedics, orthopaedics, and medical student education.

I am a physiotherapist with a clinical specialty in the management of individuals with neurological conditions and vestibular disorders. I have a keen interest in examining how the body's balance systems, including the inner ear (vestibular system), eyes (ocular system), and sensory modalities (touch, proprioception), interact with the brain to optimize movement control, functionality, physical activity, and participation outcomes for individuals affected by neurological and vestibular pathologies. This includes conditions such as multiple sclerosis, cerebellar dysfunction, traumatic brain injury, stroke, Parkinson's disease, myasthenia gravis, motor neuron disease, concussion, Meniere's disease, vestibular migraines, acoustic neuromas, and age-related vestibular dysfunction. Additionally, I am interested in the influence of lifestyle choices on vestibular system functioning and integration, particularly how factors such as physical activity, community integration, sleep, and overall wellness affect both neurological and vestibular conditions, including Meniere's disease, vestibular migraines, and age-related vestibular dysfunction.

I am a cognitive neuroscientist with a research focus on the neural basis of language. My research is focused on three related questions:

1. How is language processed in the brain?
2. How does brain damage affect language processing in individuals with aphasia, i.e. acquired language disorders?
3. What brain mechanisms support the recovery of language processing in people with aphasia who improve over time?

To address these questions, my lab studies individuals with aphasia, as well as healthy participants with normal language, using a range of state-of-the-art functional and structural neuroimaging techniques. We combine our multimodal imaging approach with comprehensive language assessments designed to quantify deficits in different components of the language processing system, such as syntactic structure, word meanings, and the selection and assembly of speech sounds.

Language Neuroscience Laboratory

Wayne Wilson is an Associate Professor in the Discipline of Audiology at the School of Health and Rehabilitation Sciences, The University of Queensland (UQ). He holds a PhD and Post-graduate Diploma in audiology and a BSc(Hons) in auditory physiology. His research interests include listening and listening difficulties in children, the objective assessment of auditory function, and clinical competence in audiology. Wayne has published >100 papers in refereed scientific journals, >10 book chapters and 3 patents; has presented >300 papers at scientific conferences including >15 key-note/opening addresses; and has secured >35 competitive research grants totaling >AUD$4.2 million.

Professor Wolvetang is an international leader in the area of pluripotent stem cell biology and human functional genomics. he initiated and leads Cell Reprogramming Australia, a collaborative framework that facilitates induced pluripotent stem cell research in Australa and is co-director of the UQ Centre in Stem Cell Ageing and Regenerative Engineering (StemCARE). He has extensive expertise in reprogramming somatic cells, differentiation and tissue engineering with adult, embryonic and induced pluripotent stem cells, genome manipulation with CRISPR, molecular biology, transcriptome analysis, high content image analysis, development and use of microfluidic devices for cell analysis, nanoparticle and scaffold design and delivery, and stem cell and cell-free regenerative medicine approaches.Professor Wolvetang has been instrumental in establishing and enabling the technology for derivation of induced pluripotent stem cells across Australia. Professor Wolvetang made the strategic decision to focus on the generation of induced pluripotent stem from patients with neurological and cardiac disorders because live human cells from such patients can usually not be obtained whereas induced pluripotent stem cells have the ability to generate every cell type of the human brain in unlimited amounts and can recapitulate the disease in the dish. Induced pluripotent stem cells combined with emerging technologies such as CRISPR-based genome editing offers a unique opportunity to study the role of individual genes and combinatorial gene regulatory pathways in the eatiology of monogenic and complex brain disorders. Indeed, combined with RNA-seq and organoid generation we are now for the first time able to gain insight into gene regulatory pathways operational in individual brain cell types of healthy and diseased individuals, investigate the connectivity and function of cells, as well as pinpoint where and when during early development such deregulated pathways lead to pathological changes. Induced pluripotent stem cells further not only provide insight into the underlying pathogenesis of neurological disorders but also constitute a valuable drugscreening platform and, following CRISPR-based gene correction, can form the basis of patient specific cellular therapies for currently incurable diseases.

Professor Wolvetang received his PhD in 1992 from the Department of Biochemistry, University of Amsterdam for his original work on peroxisomal disease (6 papers). He undertook postdoctoral studies at the Department of Biochemistry and the Institute for Reproduction and Development of Monash University, investigating apoptosis, Down syndrome and Ets transcription factors, respectively, obtaining the first evidence for an intra-chromosomal regulatory loop on chromosome 21 involving Ets2 (3 papers), and revealing the role of p53 in immune-suppression in Down syndrome (Hum Mol. Genetics). He then joined Prof Martin Pera in the Australian Stem Cell Centre in 2003 to pioneer human embryonic stem cell research in Australia, resulting in a first author Nature Biotechnology paper in 2006 identifying CD30 as a marker for genetically abnormal hESC (72 cites). He was appointed group leader of the Basic human stem cell biology laboratory in the ASCC research laboratory and senior lecturer in the Department of Anatomy and Cell biology until he accepted his current position as an independent group leader at the AIBN and Professor in stem cell biology at the University of Queensland in 2008. There he started to generate integration-free induced pluripotent stem cells from human neurological diseases such as ataxia-telangiectasia (Stem cells translational medicine). In recognition of his leadership role in this area of research he was appointed leader of the “Reprogramming and Induction of pluripotency” Collaborative Stream of the Australian Stem Cell Centre until the end of that initiative in 2011, coordinating collaborative research between eight stem cell laboratories across Australia. He subsequently initiated and is now the president of Cell Reprogramming Australia, a collaborative framework aiming to facilitate and accelerate iPS cell research in Australia and the Asia pacific region and inform the general public about reprogramming technology. His research continues to combine cell reprogramming technology, genome editing/analysis tools and microfluidic/nanoparticle based detection/ delivery technologies with the aim of creating human in vitro models of disease, unravel the underlying gene regulatory networks and enable novel cell- and delivery-based therapeutics, respectively. He further co-direct the UQ-Centre for stem cell ageing and regenerative engineering (UQ-StemCARE).

Dr Woodruff is a Professor of Pharmacology who leads a research team aiming to find new therapeutic treatments for neurodegenerative disorders. Current therapies for these diseases are vastly inadequate, and so new research is needed to identify novel targets to slow or halt their progression. Prof Woodruff’s specific research revolves around the innate immune system in the brain, and the role of neuroinflammation in propagating disease. A key focus of his current work is testing new drugs developed at the University of Queensland in models of motor neuron disease (amyotrophic lateral sclerosis), Huntington’s disease, and Parkinson's disease, as well as maintaining an active interest in acute inflammatory disorders including sepsis and ischemia-reperfusion injuries. Using a series of potent and orally active complement C5a and NLRP3 inflammasome inhibitors developed at UQ, Prof Woodruff's team has demonstrated the therapeutic potential of targeting innate immune-mediated neuroinflammation to reduce neuronal cell death in animal models of these neurodegenerative diseases. His team has recently shown that in addition to their roles in neurodegeneration, innate immune factors also play essential roles in stem and neuronal cell development during embryogenesis, revealing the widespread physiological and pathological roles of this evolutionarily ancient immune system.